Safety Profiles of Ixekizumab versus Adalimumab: 52-Week Results from a Head-to-Head Comparison in Patients With Active Psoriatic Arthritis

被引：0
|
作者：
Mease, Philip [1 ]
Smolen, Josef [2 ]
Kavanaugh, Arthur [3 ]
Nash, Peter [4 ]
Gallo, Gaia [5 ]
Liu-Leage, Soyi [5 ]
Sapin, Christophe [5 ]
Genovese, Mark [6 ]
Bessette, Louis [7 ]
机构：
[1] Univ Washington, Seattle, WA USA
[2] Med Univ Vienna, Vienna, Austria
[3] Univ Calif San Diego, La Jolla, CA 92093 USA
[4] Univ Queensland, Brisbane, Qld, Australia
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
[6] Stanford Univ, Palo Alto, CA 94304 USA
[7] Laval Univ, Quebec City, PQ, Canada
来源：
JOURNAL OF RHEUMATOLOGY | 2021年 / 48卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
125
引用
收藏
页码：1167 / 1167
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study
    Kristensen, Lars Erik
    Keiserman, Mauro
    Papp, Kim
    McCasland, Leslie
    White, Douglas
    Lu, Wenjing
    Soliman, Ahmed M.
    Eldred, Ann
    Barcomb, Lisa
    Behrens, Frank
    RHEUMATOLOGY, 2023, 62 (06) : 2113 - 2121
  • [22] Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-na?ve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H Trial
    Reich, Kristian
    Kristensen, Lars Erik
    Smith, Saxon D.
    Rich, Phoebe
    Sapin, Christophe
    Leage, Soyi Liu
    McKenzie, Robert
    Schuster, Christopher
    Riedl, Elisabeth
    Gooderham, Melinda
    DERMATOLOGY PRACTICAL & CONCEPTUAL, 2022, 12 (02):
  • [23] Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
    Wasel, Norman
    Thaci, Diamant
    French, Lars E.
    Conrad, Curdin
    Dutronc, Yves
    Gallo, Gaia
    Berggren, Lovisa
    Lacour, Jean-Philippe
    DERMATOLOGY AND THERAPY, 2020, 10 (04) : 663 - 670
  • [24] Efficacy of Ixekizumab Versus Adalimumab in Psoriatic Arthritis ( PsA) Patients With and Without Moderate-to- Severe Psoriasis: 52-Week Results from a Multicentre, Randomised Open-Label Study
    Kristensen, Lars-Erik
    Okada, Masato
    Tillett, William
    Liu-Leage, Soyi
    El Baou, Celine
    Bradley, Andrew
    de Vlam, Kurt
    Dutz, Jan
    JOURNAL OF RHEUMATOLOGY, 2021, 48 (07) : 1167 - 1168
  • [25] Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
    Norman Wasel
    Diamant Thaçi
    Lars E. French
    Curdin Conrad
    Yves Dutronc
    Gaia Gallo
    Lovisa Berggren
    Jean-Philippe Lacour
    Dermatology and Therapy, 2020, 10 : 663 - 670
  • [26] EFFICACY OF IXEKIZUMAB VERSUS ADALIMUMAB IN PSORIATIC ARTHRITIS (PSA) PATIENTS WITH AND WITHOUT MODERATE-TO-SEVERE PSORIASIS: 52-WEEK RESULTS FROM A MULTICENTRE, RANDOMIZED OPEN-LABEL STUDY
    Kristensen, Lars-Erik
    Okada, Masato
    Tillett, William
    Leage, Soyi Liu
    El Baou, Celine
    Bradley, Andrew
    Moszaros, Gabriella
    De Vlam, Kurt
    Mora Alfonso, Sergio Alexander
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S140 - S141
  • [27] Efficacy of Ixekizumab versus Adalimumab in Psoriatic Arthritis (PsA) Patients with and Without Moderate-to-severe Psoriasis: 52-week Results from a Multicentre, Randomised Open-label Study
    Kristensen, Lars Erik
    Okada, Masato
    Tillett, William
    Liu-Leage, Soyi
    El Baou, Celine
    Bradley, Andrew
    Meszaros, Gabriella
    de Vlam, Kurt
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [28] EFFICACY OF IXEKIZUMAB VERSUS ADALIMUMAB IN PSORIATIC ARTHRITIS (PSA) PATIENTS WITH AND WITHOUT MODERATE-TO-SEVERE PSORIASIS: 52-WEEK RESULTS FROM A MULTICENTRE, RANDOMISED OPEN-LABEL STUDY
    Kristensen, Lars-Erik
    Okada, Masato
    Tillett, William
    Leage, Soyi Liu
    El Baou, Celine
    Bradley, Andrew J.
    Meszaros, Gabriella
    de Vlam, Kurt
    RHEUMATOLOGY, 2021, 60
  • [29] EFFICACY AND SAFETY OF RISANKIZUMAB (RZB) FOR ACTIVE PSORIATIC ARTHRITIS (PSA): 52-WEEK RESULTS FROM KEEPSAKE 2
    Ostor, A.
    Van den Bosch, F.
    Papp, K.
    Asnal, C.
    Blanco, R.
    Aelion, J.
    Lu, W.
    Wang, Z.
    Soliman, A. M.
    Eldred, A.
    Padilla, B.
    Kivitz, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 832 - 832
  • [30] EFFICACY AND SAFETY OF RISANKIZUMAB (RZB) FOR ACTIVE PSORIATIC ARTHRITIS (PSA): 52-WEEK RESULTS FROM KEEPSAKE 1
    Kristensen, L. E.
    Keiserman, M.
    Papp, K.
    Mccasland, L.
    White, D.
    Lu, W.
    Soliman, A. M.
    Eldred, A.
    Barcomb, L.
    Behrens, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 823 - 824
12345